Annual report pursuant to Section 13 and 15(d)

Quarterly Financial Information (unaudited) (Parenthetical) (Details)

v3.3.1.900
Quarterly Financial Information (unaudited) (Parenthetical) (Details) - USD ($)
$ / shares in Units, $ in Thousands
 3 Months Ended 12 Months Ended
Dec. 31, 2015
Dec. 31, 2014
Dec. 31, 2015
Error Corrections And Prior Period Adjustments Restatement [Line Items]      
Gain on sale of business     $ 3,505
Restatement Adjustment [Member]      
Error Corrections And Prior Period Adjustments Restatement [Line Items]      
Decrease to operating expenses   $ (1,600)  
Decrease to net loss   $ (1,600)  
Decrease to basic loss per share (in dollar per shares)   $ (0.01)  
Decrease to diluted loss per share (in dollar per shares)   $ (0.02)  
Manufacturing Facility in Berkeley, California [Member] | Other Income (Expense), Net [Member]      
Error Corrections And Prior Period Adjustments Restatement [Line Items]      
Gain on sale of business $ 3,500    
Novartis [Member]      
Error Corrections And Prior Period Adjustments Restatement [Line Items]      
Upfront payment received 37,000    
Novo Nordisk [Member]      
Error Corrections And Prior Period Adjustments Restatement [Line Items]      
Upfront payment received 5,000    
Pfizer [Member]      
Error Corrections And Prior Period Adjustments Restatement [Line Items]      
Upfront payment received $ 3,800